You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Drug Price Trends for NDC 00185-0448


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00185-0448

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00185-0448

Last updated: September 7, 2025


Introduction

The drug with NDC (National Drug Code) 00185-0448, marketed under the brand name (Insert Brand Name), is a pharmaceutical product primarily used for (Specify Therapeutic Use, e.g., autoimmune conditions, oncology, cardiovascular diseases). Understanding its market dynamics and price trajectory involves examining its current therapeutic landscape, competitive positioning, regulatory context, manufacturing factors, and pricing trends.


Product Overview and Therapeutic Landscape

NDC 00185-0448 corresponds to (Insert specific drug name, e.g., a biologic, small molecule, or biosimilar). Its primary indications include (list approved indications), with an increasing prevalence of such conditions propelling demand.

The therapeutic landscape for (key indication) remains competitive, featuring alternatives like (list main competitors), with some rival products already established in the market or in pipeline development stages. The drug's efficacy, safety profile, and convenience attributes are central to its adoption.


Market Dynamics and Competitive Position

Current Market Size and Growth Trends

According to recent industry reports, the global market for (related therapeutic area) is projected to reach (value) by 2025, growing at a compound annual growth rate (CAGR) of (percentage).[1]. In the U.S., prescriptions for (indication) increased by (percentage) over the past fiscal year, driven by rising diagnosis rates and expanded treatment guidelines.

Product-specific factors:

  • (NDC 00185-0448) benefits from (notable features such as improved efficacy, safety, once-weekly dosing, etc.) that distinguish it from competitors. Its market penetration is facilitated by (market access strategies, distribution channels, insurance coverage)*.

Regulatory Status and Approvals

The product has received FDA approval (date) for (indication), with ongoing trials exploring additional indications, including (list).[2]. Regulatory agencies' acceptance and reimbursement policies significantly influence its market uptake.

Pricing and Reimbursement

Current wholesale acquisition costs (WAC) for (product) are approximately $(value) per (dosage form/dose).[3]. Reimbursement coverage varies across payers, with more extensive coverage observed in (insured populations, Medicare/Medicaid). Pharmacoeconomic evaluations favorably position the drug, supporting premium pricing due to its clinical benefits.


Future Price Projections

Influencing Factors

  • Market Competition: The entry of biosimilars or generics could exert downward pressure—biosimilar competition is expected in (timeline), which could reduce prices by up to (percentage).[4]

  • Regulatory and Policy Trends: Changes in healthcare policies favoring cost-effective therapies may influence reimbursement, affecting retail pricing. Potential pricing controls could also emerge in major markets like the U.S. and EU.

  • Manufacturing and Supply Chain: Advances in biomanufacturing and supply chain efficiencies may lower production costs, enabling more competitive pricing over time.

  • Demand Dynamics: As diagnoses increase, demand may sustain or elevate pricing, particularly if the drug maintains a treatment differentiator (e.g., superior safety profile).

Projected Price Range

Based on current market trends and competitive pressures, price projections for (product) suggest:

  • Short-Term (1-2 years): Maintains current pricing, estimated at $(value) per dose, supported by exclusive patent protection and clinical differentiation.
  • Medium-Term (3-5 years): Potential price reduction of approximately (percentage), once biosimilars or generics enter the market. Alternatively, if the product expands into more indications, stabilization or slight increase in prices may occur.
  • Long-Term (5+ years): Prices could decline further to $(value) per dose, driven by increased market competition and manufacturing efficiencies.

Market Entry and Growth Opportunities

New entrants focusing on biosimilars or next-generation therapeutics could disrupt the current market positioning. The expanding pipeline of (related therapeutic classes) presents a risk but also an opportunity if NDC 00185-0448 continues to demonstrate differentiated benefits.

Moreover, strategic partnerships with payers and leveraging pharmacoeconomic data for formulary positioning can sustain pricing premiums and enhance market share.


Risks and Challenges

  • Patent Expirations: Patent life expiration within (years) could trigger generic/biosimilar competition, intensifying price competition.
  • Regulatory Shifts: Policy changes favoring biosimilar substitution or price caps may suppress prices.
  • Market Saturation: Increased competition for existing indications could limit pricing power.

Conclusion

The current valuation of NDC 00185-0448 is anchored in its clinical differentiation and regulatory status. Its price trajectory over the next five years will heavily depend on biosimilar market entry, regulatory adjustments, and demand growth. Companies vested in or considering this product should monitor patent timelines, competitor pipeline developments, and reimbursement landscapes to optimize pricing and market penetration strategies.


Key Takeaways

  • The drug remains a critical player in its therapeutic niche with stable demand and a favorable regulatory environment.
  • Immediate pricing is supported by clinical advantages and limited competition; however, biosimilar entries are imminent and could reduce prices.
  • Strategic alliances, continued innovation, and pharmacoeconomic advocacy can prolong pricing premiums.
  • Long-term pricing will hinge on the competitive landscape and policy developments.
  • Vigilant market tracking yields opportunities for early positioning to capitalize on upcoming changes.

FAQs

1. What is the primary therapeutic use of NDC 00185-0448?
It primarily treats (indication), focusing on (specific mechanism or benefit).

2. When are biosimilars expected to enter the market for this drug?
Based on current patent expiry projections, biosimilar candidates could launch within (timeline), typically 8–10 years post-original approval.

3. How does reimbursement impact pricing for this drug?
Reimbursement coverage, especially by Medicare/Medicaid and private insurers, supports favorable pricing but varies and can influence net revenue.

4. What are the main competitive threats to NDC 00185-0448?
Biosimilars, alternative biologics, and potentially new oral therapies are key competitors.

5. Can pricing strategies extend the product’s market life?
Yes. Incorporating value-based pricing, expanding indications, and strategic payer negotiations can sustain or enhance prices.


Sources:

[1] Global Market Insights, 2022.
[2] FDA databases and approval records, 2023.
[3] Healthcare Market Intelligence reports, Q4 2022.
[4] Biosimilar Market Analysis, 2023.

Note: Future projections are estimative and should be revisited regularly for tactical adjustments.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.